9
Participants
Start Date
March 31, 2013
Primary Completion Date
October 23, 2018
Study Completion Date
October 23, 2018
Decitabine
administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
Vorinostat
200 mg by mouth (PO) twice a day on days 6-15
Interleukin-2
6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
Natural killer (NK) cells
infusion intravenously (IV) over 15 to 60 minutes day 17
Masonic Cancer Center, University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Collaborators (1)
Masonic Cancer Center, University of Minnesota
OTHER
Mayo Clinic
OTHER